Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia.


Journal Article

This clinical study, begun in 1975, tested the efficacy of early and delayed intensification treatments in children with acute lymphoblastic leukemia. Regardless of presenting features, all patients received 4 weeks of conventional induction therapy with daily prednisone and weekly vincristine and daunorubicin. One-third were randomized to receive, in addition, two doses of asparaginase during induction therapy, while another one-third received four doses of both asparaginase and cytarabine after remission induction. Preventive central nervous system therapy uniformly included 2400 rads cranial irradiation and five doses of intrathecal methotrexate. Remissions were maintained with daily p.o. mercaptopurine and weekly i.v. methotrexate. Of the 277 assessable patients, 254 (92%) entered complete remission, and 102 (37%) remain clinically free of leukemia for 4.6 to 8.0 years (median, 6.3 years). The three treatment groups showed no significant differences in either remission induction rate or outcome, even when the analysis was based on risk assignment. A "late intensification" phase of therapy, added to the maintenance protocol for 65 patients who had been in continuous complete remission for 14 to 30 months, failed to extend remission durations, as judged from statistical comparison with matched controls (p = 0.84). When tested as a time-dependent covariate in the Cox proportional-hazards model, delayed intensification again showed no important effect on duration of complete remission. We conclude that limited early or aggressive late intensification of therapy, as described here, does not improve outcome in childhood acute lymphoblastic leukemia.

Full Text

Duke Authors

Cited Authors

  • Pui, CH; Aur, RJ; Bowman, WP; Dahl, GV; Dodge, RK; George, SL; Ochs, J; Kalwinsky, DK; Abromowitch, M; Hustu, HO

Published Date

  • August 1, 1984

Published In

Volume / Issue

  • 44 / 8

Start / End Page

  • 3593 - 3598

PubMed ID

  • 6589042

Pubmed Central ID

  • 6589042

International Standard Serial Number (ISSN)

  • 0008-5472


  • eng

Conference Location

  • United States